Načítá se...
Pathologic response after neoadjuvant chemotherapy in resectable non-small cell lung cancers: proposal for the use of “major pathologic response” as a surrogate endpoint
Improvements in outcomes for patients with resectable lung cancers have plateaued. Clinical trials in this disease using overall survival as the primary endpoint require a decade or longer to complete, are expensive, and limit innovation. A surrogate for survival, such as pathologic response to neoa...
Uloženo v:
| Vydáno v: | Lancet Oncol |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4734624/ https://ncbi.nlm.nih.gov/pubmed/24384493 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70334-6 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|